samedan logo
 
 
spacer
home > epc > autumn 2018 > clinical service
PUBLICATIONS
European Pharmaceutical Contractor

Clinical Service

With the NHS currently facing some of its greatest challenges in a 70-year history, clinical trials for new treatments and technologies could provide the solutions to seemingly insurmountable problems: endless surgery waiting lists, bed-blocking, and clinicians and nurses stretched to their limit. Do public-private partnerships between the NHS and medical technology developers hold the key?

Successful outcomes in device development and the development of clinical and health economic benefits rely heavily on the strong partnerships between clinicians and med-tech developers, with both parties committed to improving outcomes for patients. The clinicians that embrace innovation and that are forward-thinking must be championed. Collaborating with those willing to invest in and introduce evidence-based therapies to simplify treatments will help build a more robust health system that is moving forward, rather than stuck in its tracks under strain.

2018 marks the NHS’s 70th birthday, and, as the British institution celebrates 70 years of service, the general public rushed to express their gratitude; from cradle to grave, the NHS is hailed for its care for every citizen, no matter their condition, circumstance, or means.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bernard Ross is the CEO at Sky Medical Technology, a UK-based medical devices company. Bernard and the company develop a range of products tailored to the needs of different medical application areas, selling both directly and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include reduction of oedema, prevention of venous thromboembolism, wound healing, and elite sport recovery.
spacer
Bernard Ross
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Continues Commitment to Oncology Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement